Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7097 USD | +7.79% | -6.07% | +23.90% |
Mar. 14 | Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 14 | Transcript : Vaxart, Inc., 2023 Earnings Call, Mar 14, 2024 |
Business Summary
Number of employees: 109
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Oral Recombinant Protein Vaccines
100.0
%
| 0 | 100.0 % | 7 | 100.0 % | +6,796.26% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 7 | 100.0 % | +6,796.26% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Sean Tucker
FOU | Founder | - | 03-12-31 |
Phillip Eric Lee
DFI | Director of Finance/CFO | 37 | 22-12-18 |
Michael Finney
CHM | Chairman | 65 | 07-06-30 |
James Cummings
CTO | Chief Tech/Sci/R&D Officer | - | 21-09-26 |
Chief Tech/Sci/R&D Officer | - | 22-08-30 | |
Edward Berg
LAW | General Counsel | - | 22-02-13 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Yedid
BRD | Director/Board Member | 66 | 19-10-24 |
Elaine Heron
BRD | Director/Board Member | 76 | 22-08-24 |
Michael Finney
CHM | Chairman | 65 | 07-06-30 |
Sean Tucker
FOU | Founder | - | 03-12-31 |
David Wheadon
BRD | Director/Board Member | 66 | 21-04-20 |
Director/Board Member | 73 | 22-08-03 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 174,368,704 | 172,181,535 ( 98.75 %) | 507,020 ( 0.2908 %) | 98.75 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.90% | 126M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- VXRT Stock
- Company Vaxart, Inc.